Citations (77)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (16)
Florenzo Iannone, Fabrizio Conti, Alberto Cauli, Alberto Farina & Roberto Caporali. (2022) Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence. Journal of Inflammation Research 15, pages 3259-3267.
Read now
Read now
Roberto Caporali, Yannick Allanore, Rieke Alten, Bernard Combe, Patrick Durez, Florenzo Iannone, Mike T. Nurmohamed, Sang Joon Lee, Taek Sang Kwon, Jean Soo Choi, Gahee Park & Dae Hyun Yoo. (2021) Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. Expert Review of Clinical Immunology 17:1, pages 85-100.
Read now
Read now
Yuji Nozaki, Yasuaki Nagare, Chisato Ashida, Daisuke Tomita, Akinori Okada, Asuka Inoue, Koji Kinoshita, Masanori Funauchi & Itaru Matsumura. (2018) Infliximab dose adjustment can improve the clinical and radiographic outcomes of rheumatoid arthritis patients: REVIVE study results. Biologics: Targets and Therapy 12, pages 171-182.
Read now
Read now
Masataka Umeda, Tomohiro Koga, Kunihiro Ichinose, Ayuko Takatani, Takashi Igawa, Toshimasa Shimizu, Shoichi Fukui, Ayako Nishino, Yoshiro Horai, Yasuko Hirai, Shin-Ya Kawashiri, Naoki Iwamoto, Mami Tamai, Hideki Nakamura, Tomoki Origuchi, Toshiyuki Aramaki, Yukitaka Ueki, Akitomo Okada, Keita Fujikawa, Naoki Matsuoka & Atsushi Kawakami. (2018) Efficacy of infliximab as a switched biologic in rheumatoid arthritis patients in daily clinical practice. Immunological Medicine 41:4, pages 181-186.
Read now
Read now
Daisuke Kobayashi, Satoshi Ito, Chinatsu Takai, Eriko Hasegawa, Yumi Nomura, Hiroshi Otani, Asami Abe, Hajime Ishikawa, Akira Murasawa, Ichiei Narita & Kiyoshi Nakazono. (2018) Efficacy and safety of infliximab: A comparison with other biological disease-modifying anti-rheumatic drugs. Modern Rheumatology 28:4, pages 599-605.
Read now
Read now
Koji Takasugi, Keiichiro Nishida, Masamitsu Natsumeda, Misuzu Yamashita, Wataru Yamamoto & Kazuhiko Ezawa. (2018) IL-6 is an independent predictive factor of drug survival after dose escalation of infliximab in patients with rheumatoid arthritis. Modern Rheumatology 28:3, pages 452-460.
Read now
Read now
Ayaka Yoshikawa, Shuzo Yoshida, Yuko Kimura, Nao Tokai, Yohei Fujiki, Takuya Kotani, Yoko Matsumura, Tohru Takeuchi & Shigeki Makino. (2018) Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study. Modern Rheumatology 28:2, pages 227-234.
Read now
Read now
Shigeto Kobayashi & Toru Yoshinari. (2017) A multicenter, open-label, long-term study of three-year infliximab administration in Japanese patients with ankylosing spondylitis. Modern Rheumatology 27:1, pages 142-149.
Read now
Read now
Masao Nawata, Kazuyoshi Saito, Shunsuke Fukuyo, Shintaro Hirata & Yoshiya Tanaka. (2016) Clinically relevant radiographic progression in joint destruction in RA patients with abnormal MMP-3 or high levels of CRP despite 1-year treatment with infliximab. Modern Rheumatology 26:6, pages 807-812.
Read now
Read now
Yasutaka Kadota, Keiichiro Nishida, Kenzo Hashizume, Yoshihisa Nasu, Ryuichi Nakahara, Tomoko Kanazawa, Masatsugu Ozawa, Ryozo Harada, Takahiro Machida & Toshifumi Ozaki. (2016) Risk factors for surgical site infection and delayed wound healing after orthopedic surgery in rheumatoid arthritis patients. Modern Rheumatology 26:1, pages 68-74.
Read now
Read now
Tsutomu Takeuchi, Hisashi Yamanaka, Yoshiya Tanaka, Takeo Sakurai, Kazuyoshi Saito, Hideo Ohtsubo, Sang Joon Lee & Yoshihiro Nambu. (2015) Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Modern Rheumatology 25:6, pages 817-824.
Read now
Read now
Eri Sato, Eiichi Tanaka, Ayako Nakajima, Eisuke Inoue, Yoko Shimizu, Rei Yamaguchi, Moeko Ochiai, Kumi Shidara, Daisuke Hoshi, Naoki Sugimoto, Yohei Seto, Atsuo Taniguchi, Shigeki Momohara & Hisashi Yamanaka. (2015) Assessment of the effectiveness of golimumab 50-mg and 100-mg regimens in patients with rheumatoid arthritis in daily practice. Modern Rheumatology 25:4, pages 528-533.
Read now
Read now
Akito Takamura, Shintaro Hirata, Hayato Nagasawa, Hideto Kameda, Yohei Seto, Tatsuya Atsumi, Makoto Dohi, Takao Koike, Nobuyuki Miyasaka & Masayoshi Harigai. (2013) A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology. Modern Rheumatology 23:2, pages 297-303.
Read now
Read now
Yukihiko Saeki, Toshihiro Matsui, Koichiro Saisho & Shigeto Tohma. (2012) Current treatments of rheumatoid arthritis: from the ‘NinJa’ registry. Expert Review of Clinical Immunology 8:5, pages 455-465.
Read now
Read now
Masaki Takeuchi, Yuri Asukata, Tatsukata Kawagoe, Norihiko Ito, Tadayuki Nishide & Nobuhisa Mizuki. (2012) Infliximab Monotherapy Versus Infliximab and Colchicine Combination Therapy in Patients with Behçet’s Disease. Ocular Immunology and Inflammation 20:3, pages 193-197.
Read now
Read now
Hiroki Wakabayashi, Masahiro Hasegawa, Yosuke Nishioka, Akihiro Sudo & Kusuki Nishioka. (2012) Which subgroup of rheumatoid arthritis patients benefits from switching to tocilizumab versus etanercept after previous infliximab failure? A retrospective study. Modern Rheumatology 22:1, pages 116-121.
Read now
Read now
Articles from other publishers (61)
Shuo-Fu Chen, Fu-Chiang Yeh, Ching-Yun Chen & Hui-Yin Chang. (2023) Tailored therapeutic decision of rheumatoid arthritis using proteomic strategies: how to start and when to stop?. Clinical Proteomics 20:1.
Crossref
Crossref
Tsutomu Takeuchi. (2023) Structural, nonclinical, and clinical features of ozoralizumab: A novel tumour necrosis factor inhibitor. Modern Rheumatology 33:6, pages 1059-1067.
Crossref
Crossref
Yuichi Ando, Hiroyuki Nishiyama, Hideki Shimodaira, Nao Takano, Emiko Sakaida, Koji Matsumoto, Koki Nakanishi, Hideki Sakai, Shokichi Tsukamoto, Keigo Komine, Yoshinari Yasuda, Taigo Kato, Yutaka Fujiwara, Takafumi Koyama, Hiroshi Kitamura, Takashige Kuwabara, Atsushi Yonezawa, Yuta Okumura, Kimikazu Yakushijin, Kazuki Nozawa, Hideaki Goto, Takeshi Matsubara, Junichi Hoshino & Motoko Yanagita. (2023) Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. International Journal of Clinical Oncology.
Crossref
Crossref
Tsutomu Takeuchi, Yukihiro Chino, Masafumi Kawanishi, Megumi Nakanishi, Hirotaka Watase, Yoko Mano, Yuri Sato, Saeko Uchida & Yoshiya Tanaka. (2023) Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials. Arthritis Research & Therapy 25:1.
Crossref
Crossref
Tsutomu Takeuchi. (2022) Cytokines and cytokine receptors as targets of immune-mediated inflammatory diseases—RA as a role model. Inflammation and Regeneration 42:1.
Crossref
Crossref
Toshihiro Kita, Shinya Ashizuka, Teruyuki Takeda, Takayuki Matsumoto, Naoki Ohmiya, Hiroshi Nakase, Satoshi Motoya, Hidehisa Ohi, Keiichi Mitsuyama, Tadakazu Hisamatsu, Shuji Kanmura, Naoya Kato, Shunji Ishihara, Masanao Nakamura, Tomohiko Moriyama, Masayuki Saruta, Ryoichi Nozaki, Shojiro Yamamoto, Haruhiko Inatsu, Koji Watanabe & Kazuo Kitamura. (2022) Adrenomedullin for biologic‐resistant Crohn's disease: A randomized, double‐blind, placebo‐controlled phase 2a clinical trial. Journal of Gastroenterology and Hepatology 37:11, pages 2051-2059.
Crossref
Crossref
Johanna Elin Gehin, Guro Løvik Goll, Marthe Kirkesæther Brun, Meghna Jani, Nils Bolstad & Silje Watterdal Syversen. (2022) Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine. BioDrugs 36:6, pages 731-748.
Crossref
Crossref
Eri Sugano, Eiichi Tanaka, Eisuke Inoue, Ryoko Sakai, Mai Abe, Kumiko Saka, Naohiro Sugitani, Moeko Ochiai, Rei Yamaguchi, Yoko Higuchi, Naoki Sugimoto, Katsunori Ikari, Ayako Nakajima, Hisashi Yamanaka & Masayoshi Harigai. (2022) Differences in patients’ population and efficacy/effectiveness of biologic disease–modifying antirheumatic drugs between randomized controlled trials and real-world settings in patients with rheumatoid arthritis – using the IORRA cohort. Modern Rheumatology 32:4, pages 675-685.
Crossref
Crossref
Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll, Marthe Kirkesæther Brun, Øystein Sandanger, Kristin Hammersbøen Bjørlykke, Joseph Sexton, Inge Christoffer Olsen, Johanna Elin Gehin, David John Warren, Rolf Anton Klaasen, Geir Noraberg, Trude Jannecke Bruun, Christian Kvikne Dotterud, Maud Kristine Aga Ljoså, Anne Julsrud Haugen, Rune Johan Njålla, Camilla Zettel, Carl Magnus Ystrøm, Yngvill Hovde Bragnes, Svanaug Skorpe, Turid Thune, Kathrine Aglen Seeberg, Brigitte Michelsen, Ingrid Marianne Blomgren, Eldri Kveine Strand, Pawel Mielnik, Roald Torp, Cato Mørk, Tore K. Kvien, Jørgen Jahnsen, Nils Bolstad & Espen A. Haavardsholm. (2021) Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases. JAMA 326:23, pages 2375.
Crossref
Crossref
Bernard Combe, Yannick Allanore, Rieke Alten, Roberto Caporali, Patrick Durez, Florenzo Iannone, Michael T. Nurmohamed, Mondher Toumi, Sang Joon Lee, Taek Sang Kwon, Jiwon Noh, Gahee Park & Dae Hyun Yoo. (2021) Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials. Arthritis Research & Therapy 23:1.
Crossref
Crossref
Kazuto Nakae, Sho Masui, Atsushi Yonezawa, Motomu Hashimoto, Ryu Watanabe, Koichi Murata, Kosaku Murakami, Masao Tanaka, Hiromu Ito, Kotoko Yokoyama, Noriko Iwamoto, Takashi Shimada, Miyuki Nakamura, Masaya Denda, Kotaro Itohara, Shunsaku Nakagawa, Yasuaki Ikemi, Satoshi Imai, Takayuki Nakagawa, Makoto Hayakari & Kazuo Matsubara. (2021) Potential application of measuring serum infliximab levels in rheumatoid arthritis management: A retrospective study based on KURAMA cohort data. PLOS ONE 16:10, pages e0258601.
Crossref
Crossref
Takanori Inagaki, Tatsuya Isesaki, Kumi Kawana & Ryohkan Funakoshi. (2021) Viability of a Serum Infliximab Concentration-Detecting Reagent as a Qualitative Assay for an Infliximab Biosimilar. Biological and Pharmaceutical Bulletin 44:9, pages 1272-1279.
Crossref
Crossref
Serena Patel & Meenu Wadhwa. (2021) Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19. Biomedicine & Pharmacotherapy 140, pages 111785.
Crossref
Crossref
Rene Westhovens, Piotr Wiland, Marek Zawadzki, Delina Ivanova, Alfredo Berrocal Kasay, Elias Chalouhi El-Khouri, Éva Balázs, Sergii Shevchuk, Larisa Eliseeva, Mykola Stanislavchuk, Roman Yatsyshyn, Paweł Hrycaj, Janusz Jaworski, Vyacheslav Zhdan, Jakub Trefler, Pavel Shesternya, Sang Joon Lee, Sung Hyun Kim, Jee Hye Suh, Seul Gi Lee, Noo Ri Han & Dae Hyun Yoo. (2021) Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. Rheumatology 60:5, pages 2277-2287.
Crossref
Crossref
Jérémie Sellam, Jacques Morel, Anne Tournadre, Yoram Bouhnik, Divi Cornec, Valérie Devauchelle-Pensec, Philippe Dieudé, Philippe Goupille, Denis Jullien, Nicolas Kluger, Estibaliz Lazaro, Benoit Le Goff, Victor de Lédinghen, Thierry Lequerré, Gaëtane Nocturne, Raphaèle Seror, Marie-Elise Truchetet, Frank Verhoeven, Thao Pham & Christophe Richez. (2021) Practical management of patients on anti-TNF therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). Joint Bone Spine 88:2, pages 105174.
Crossref
Crossref
Silje W Syversen, Guro L Goll, Kristin K Jørgensen, Inge C Olsen, Øystein Sandanger, Johanna E Gehin, David J Warren, Joseph Sexton, Cato Mørk, Jørgen Jahnsen, Tore K Kvien, Nils Bolstad & Espen A Haavardsholm. (2020) Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study). Trials 21:1.
Crossref
Crossref
Tsutomu Takeuchi. (2020) Pursuit and New Trend in Rheumatoid Arthritis関節リウマチ診療の軌跡と新たな潮流. Nihon Naika Gakkai Zasshi 109:9, pages 1669-1684.
Crossref
Crossref
José Rosas, María Martín-López, Teresa Otón, Alejandro Balsa, Jaime Calvo-Alén, Raimon Sanmartí, Jesús Tornero & Loreto Carmona. (2020) Practical aspects of biological throught levels and antidrug antibodies in rheumatoid arthritis and spondyloarthritis. Reumatología Clínica (English Edition) 16:5, pages 378-385.
Crossref
Crossref
José Rosas, María Martín-López, Teresa Otón, Alejandro Balsa, Jaime Calvo-Alén, Raimon Sanmartí, Jesús Tornero & Loreto Carmona. (2020) Aspectos prácticos de la medición de los niveles de fármacos biológicos y de anticuerpos antifármaco en artritis reumatoide y espondiloartritis. Reumatología Clínica 16:5, pages 378-385.
Crossref
Crossref
Nastya Kharlamova, Christina Hermanrud, Nicky Dunn, Malin Ryner, Karen Hambardzumyan, Nancy Vivar Pomiano, Per Marits, Inger Gjertsson, Saedis Saevarsdottir, Rille Pullerits & Anna Fogdell-Hahn. (2020) Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier. Frontiers in Immunology 11.
Crossref
Crossref
Maurizio Benucci, Valentina Grossi, Mariangela Manfredi, Arianna Damiani, Maria Infantino, Paolo Moscato, Luigi Cinquanta, Elisa Gremese, Barbara Tolusso, Luca Petricca, Anna Laura Fedele, Stefano Alivernini, Fabiola Atzeni, Giovanni Minisola & Roberto Verna. (2020) Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity. Annals of Laboratory Medicine 40:2, pages 101-113.
Crossref
Crossref
Sho Masui, Atsushi Yonezawa, Kazushi Izawa, Makoto Hayakari, Kayoko Asakura, Risa Taniguchi, Masahiko Isa, Hirofumi Shibata, Takahiro Yasumi, Ryuta Nishikomori, Junko Takita & Kazuo Matsubara. (2019) Plasma infliximab monitoring contributes to optimize Takayasu arteritis treatment: a case report. Journal of Pharmaceutical Health Care and Sciences 5:1.
Crossref
Crossref
Johanna Elin Gehin, Guro Løvik Goll, David John Warren, Silje Watterdal Syversen, Joseph Sexton, Eldri Kveine Strand, Tore Kristian Kvien, Nils Bolstad & Elisabeth Lie. (2019) Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study. Arthritis Research & Therapy 21:1.
Crossref
Crossref
Logan J. Harper, Meghann McCarthy, Manuel L. Ribeiro Neto, Rory Hachamovitch, Karla Pearson, Barbara Bonanno, Josephine Shaia, Richard Brunken, Emer Joyce & Daniel A. Culver. (2019) Infliximab for Refractory Cardiac Sarcoidosis. The American Journal of Cardiology 124:10, pages 1630-1635.
Crossref
Crossref
María José Fobelo Lozano, Reyes Serrano Giménez & Susana Sánchez Fidalgo. (2019) Therapeutic drug monitoring of infliximab in spondyloarthritis. A review of the literature. British Journal of Clinical Pharmacology 85:10, pages 2264-2279.
Crossref
Crossref
Niels Graudal, Benjamin Skov Kaas-Hansen, Louise Guski, Thorbjørn Hubeck-Graudal, Nicky J. Welton & Gesche Jürgens. (2019) Different Original and Biosimilar TNF Inhibitors Similarly Reduce Joint Destruction in Rheumatoid Arthritis—A Network Meta-Analysis of 36 Randomized Controlled Trials. International Journal of Molecular Sciences 20:18, pages 4350.
Crossref
Crossref
Ping Ji, Nikolay Nikolov, Sally Seymour, Rachel Glaser, Yupeng Ren, Liang Li, Anshu Marathe, Yunzhao Ren, Jianmeng Chen, Lei He, Dipak Pisal, Shalini Wickramaratne Senarath Yapa, Yaning Wang & Chandrahas Sahajwalla. (2019) A Novel Pharmacokinetic Bridging Strategy to Support a Change in the Route of Administration for Biologics. Journal of Pharmaceutical Sciences 108:7, pages 2490-2499.
Crossref
Crossref
Honghui Zhou & Diane R. MouldDiane R. Mould, Richard N. Upton & Jessica Wojciechowski. 2019. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune‐Mediated Inflammatory Diseases. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune‐Mediated Inflammatory Diseases
255
284
.
Chiyo K. Imamura. (2019) Therapeutic drug monitoring of monoclonal antibodies: Applicability based on their pharmacokinetic properties. Drug Metabolism and Pharmacokinetics 34:1, pages 14-18.
Crossref
Crossref
. (2018) UEG Week 2018 Oral Presentations. United European Gastroenterology Journal 6:S8.
Crossref
Crossref
María Martín-López, Loreto Carmona, Alejandro Balsa, Jaime Calvo-Alén, Raimon Sanmartí, Jesús Tornero & José Rosas. (2018) Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review. Rheumatology International 38:6, pages 975-983.
Crossref
Crossref
Taio Naniwa, Shiho Iwagaitsu & Mikiko Kajiura. (2018) Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors. International Journal of Rheumatic Diseases 21:3, pages 673-687.
Crossref
Crossref
Tsutomu Takeuchi, Nobuyuki Miyasaka, Takashi Inui, Toshiro Yano, Toru Yoshinari, Tohru Abe & Takao Koike. (2017) High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study. Arthritis Research & Therapy 19:1.
Crossref
Crossref
Yasushi Kondo, Yuko Kaneko, Hiroaki Sugiura, Shunsuke Matsumoto, Naoshi Nishina, Masataka Kuwana, Masahiro Jinzaki & Tsutomu Takeuchi. (2017) Pre-treatment interleukin-6 levels strongly affect bone erosion progression and repair detected by magnetic resonance imaging in rheumatoid arthritis patients. Rheumatology 56:7, pages 1089-1094.
Crossref
Crossref
Hideshi Torii, Masayuki Nakano, Toshiro Yano, Kazuoki Kondo & Hidemi Nakagawa. (2016) Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study. The Journal of Dermatology 44:5, pages 552-559.
Crossref
Crossref
Hiroki Wakabayashi, Hitoshi Inada, Yosuke Nishioka, Masahiro Hasegawa, Akihiro Sudo & Kusuki Nishioka. (2016) Maintenance of efficacy and safety with subcutaneous golimumab in rheumatoid arthritis patients with low disease activity who previously received TNF inhibitors. Clinical Rheumatology 36:4, pages 941-946.
Crossref
Crossref
Roy Fleischmann, Vanita Tongbram, Ronald van Vollenhoven, Derek H Tang, James Chung, David Collier, Shilpa Urs, Kerigo Ndirangu, George Wells & Janet Pope. (2017) Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor–methotrexate combination therapy versus triple therapy in rheumatoid arthritis. RMD Open 3:1, pages e000371.
Crossref
Crossref
Shinichi Takatsuki, Kazuyoshi Saito, Fukiko Ichida & Tsutomu Saji. 2017. Kawasaki Disease. Kawasaki Disease
231
237
.
José Inciarte-Mundo, Julio Ramirez, Maria Victoria Hernández, Virginia Ruiz-Esquide, Andrea Cuervo, Sonia Raquel Cabrera-Villalba, Mariona Pascal, Jordi Yagüe, Juan D. Cañete & Raimon Sanmarti. (2016) Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. Arthritis Research & Therapy 18:1.
Crossref
Crossref
Toshifumi Hibi, Shunsei Hirohata, Hirotoshi Kikuchi, Ukihide Tateishi, Noriko Sato, Kunihiko Ozaki, Kazuoki Kondo & Yoshiaki Ishigatsubo. (2016) Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease. Medicine 95:24, pages e3863.
Crossref
Crossref
Satoko Hayashi, Katsuya Suzuki, Keiko Yoshimoto, Masaru Takeshita, Takahiko Kurasawa, Kunihiro Yamaoka & Tsutomu Takeuchi. (2015) Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate. Rheumatology and Therapy 3:1, pages 155-166.
Crossref
Crossref
DR Mould, G D'Haens & RN Upton. (2016) Clinical Decision Support Tools: The Evolution of a Revolution. Clinical Pharmacology & Therapeutics 99:4, pages 405-418.
Crossref
Crossref
Tatsuya Koike & Kentaro Inui. (2015) How can the treatment of rheumatoid arthritis be improved in Japan?. International Journal of Clinical Rheumatology 10:4, pages 235-244.
Crossref
Crossref
Diane R. Mould & Marla C. Dubinsky. (2015) Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies. The Journal of Clinical Pharmacology 55:S3, pages S51-S59.
Crossref
Crossref
Izumi Kurata, Hiroto Tsuboi, Hidenori Takahashi, Saori Abe, Hiroshi Ebe, Shinya Hagiwara, Naoto Umeda, Yuya Kondo, Hiroshi Ogishima, Takeshi Suzuki, Isao Matsumoto, Sujin Hoshi, Tetsuro Oshika & Takayuki Sumida. (2015) Successful Treatment with Infliximab for Refractory Uveitis in a Hemodialysis Patient with Behçet's Disease and a Review of the Literature for Infliximab Use in Patients on Hemodialysis. Internal Medicine 54:12, pages 1553-1557.
Crossref
Crossref
Yoshishige Miyabe, Chie Miyabe & Toshihiro Nanki. (2014) Could retinoids be a potential treatment for rheumatic diseases?. Rheumatology International 35:1, pages 35-41.
Crossref
Crossref
Tzeyu L. Michaud, Young Hee Rho, Tatyana Shamliyan, Karen M. Kuntz & Hyon K. Choi. (2014) The Comparative Safety of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Meta-analysis Update of 44 Trials. The American Journal of Medicine 127:12, pages 1208-1232.
Crossref
Crossref
Selda Celik, Yusuf Yazici & Hasan Yazici. (2014) Are sample sizes of randomized clinical trials in rheumatoid arthritis too large?. European Journal of Clinical Investigation 44:11, pages 1034-1044.
Crossref
Crossref
Koji Kimura, Risa Takayanagi, Haruko Yokoyama & Yasuhiko Yamada. (2014) Theory-based Analysis of the Anti-inflammatory Effect of TNF Inhibitors on Rheumatoid Arthritis. Drug Metabolism and Pharmacokinetics 29:3, pages 272-277.
Crossref
Crossref
Rieke Alten & Filip van den Bosch. (2014) Dose optimization of infliximab in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases 17:1, pages 5-18.
Crossref
Crossref
Grith Eng, Michael B. Stoltenberg, Marcin Szkudlarek, Pierre N. Bouchelouche, Robin Christensen, Henning Bliddal & Else Marie Bartels. (2013) Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: A systematic review of cohort studies with focus on dose. Seminars in Arthritis and Rheumatism 43:2, pages 144-151.
Crossref
Crossref
Yoshishige Miyabe, Chie Miyabe, Yoshiko Iwai, Aiko Takayasu, Shin Fukuda, Waka Yokoyama, Jun Nagai, Masahiro Jona, Yasunori Tokuhara, Ryunosuke Ohkawa, Harald M. Albers, Huib Ovaa, Junken Aoki, Jerold Chun, Yutaka Yatomi, Hiroshi Ueda, Masayuki Miyasaka, Nobuyuki Miyasaka & Toshihiro Nanki. (2013) Necessity of Lysophosphatidic Acid Receptor 1 for Development of Arthritis. Arthritis & Rheumatism 65:8, pages 2037-2047.
Crossref
Crossref
XIXI MA & SHENGQIAN XU. (2013) TNF inhibitor therapy for rheumatoid arthritis. Biomedical Reports 1:2, pages 177-184.
Crossref
Crossref
Aatke van der Maas, Bart JF van den Bemt, Gertjan Wolbink, Frank HJ van den Hoogen, Piet LCM van Riel & Alfons A den Broeder. (2012) Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study. BMC Musculoskeletal Disorders 13:1.
Crossref
Crossref
Hideshi TORII, Noriko SATO, Toru YOSHINARI & Hidemi NAKAGAWA. (2011) Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: An analysis of Japanese clinical trials of infliximab. The Journal of Dermatology 39:3, pages 253-259.
Crossref
Crossref
Ronald F. van Vollenhoven. (2011) Unresolved issues in biologic therapy for rheumatoid arthritis. Nature Reviews Rheumatology 7:4, pages 205-215.
Crossref
Crossref
Koichi Amano. (2011) 1. TNF Inhibitors. Nihon Naika Gakkai Zasshi 100:10, pages 2966-2971.
Crossref
Crossref
Tsutomu Takeuchi & Hideto Kameda. (2010) The Japanese experience with biologic therapies for rheumatoid arthritis. Nature Reviews Rheumatology 6:11, pages 644-652.
Crossref
Crossref
Takako Ito, Koh-Hei Sonoda, Kuniaki Hijioka, Takeshi Fujimoto & Tatsuro Ishibashi. (2010) Acquired resistance to infliximab against uveitis due to Behçet’s disease after one year of administration. Japanese Journal of Ophthalmology 54:5, pages 502-504.
Crossref
Crossref
Yu Sakuma, Katsunori Ikari, Takuji Iwamoto, Asami Tokita & Shigeki Momohara. (2010) Reparative radiological changes of the hip joint in rheumatoid arthritis: Do these findings indicate the true repair of the joint?. Joint Bone Spine 77:3, pages 278-279.
Crossref
Crossref
Motohiko Tanino, Ryo Matoba, Seiji Nakamura, Hideto Kameda, Kouichi Amano, Toshitsugu Okayama, Hayato Nagasawa, Katsuya Suzuki, Kenichi Matsubara & Tsutomu Takeuchi. (2009) Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells. Biochemical and Biophysical Research Communications 387:2, pages 261-265.
Crossref
Crossref